---
title: "Axsome settles Auvelity patent litigation with Teva"
date: "2025-02-10 17:41:45"
summary: "Axsome Therapeutics (NASDAQ:AXSM) stock rallied 15% in morning trading on news it has settled patent litigation with Teva (NYSE:TEVA) over its antidepressant drug Auvelity. Axsome (NASDAQ:AXSM) had sued for patent infringement after Teva (NYSE:TEVA) filed an application with the FDA to market a generic version of the Axsome (AXSM) drug..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445064010/image_1445064010.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Axsome Therapeutics (NASDAQ:[AXSM](https://seekingalpha.com/symbol/AXSM "Axsome Therapeutics, Inc.")) stock rallied 15% in morning trading on news it has settled patent litigation with Teva (NYSE:[TEVA](https://seekingalpha.com/symbol/TEVA "Teva Pharmaceutical Industries Limited")) over its antidepressant drug Auvelity.

Axsome (NASDAQ:[AXSM](https://seekingalpha.com/symbol/AXSM "Axsome Therapeutics, Inc.")) had sued for patent infringement after Teva (NYSE:[TEVA](https://seekingalpha.com/symbol/TEVA "Teva Pharmaceutical Industries Limited")) filed an application with the FDA to market a generic version of the Axsome ([AXSM](https://seekingalpha.com/symbol/AXSM "Axsome Therapeutics, Inc.")) drug before the expiration of certain patents.

Under the settlement, Teva ([TEVA](https://seekingalpha.com/symbol/TEVA "Teva Pharmaceutical Industries Limited")) will be granted a license by Axsome ([AXSM](https://seekingalpha.com/symbol/AXSM "Axsome Therapeutics, Inc.")) to market a generic version of the drug on or after March 31, 2039, if Axsome ([AXSM](https://seekingalpha.com/symbol/AXSM "Axsome Therapeutics, Inc.")) receives FDA pediatric exclusivity for the product. If it does not, Teva ([TEVA](https://seekingalpha.com/symbol/TEVA "Teva Pharmaceutical Industries Limited")) will be allowed to market its generic on or after Sept. 30, 2038, pending FDA approval.

The settlement will be submitted for review by the U.S. Federal Trade Commission and Department of Justice.

[seekalpha](https://seekingalpha.com/news/4405591-axsome-settles-auvelity-patent-litigation-with-teva)
